Legend Biotech to Highlight Continued Progress in the Treatm

Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI

Related Keywords

China , United States , New Jersey , France , French , Chinese , American , Ciltacabtagene Autoleucel , Hemophagocytic Lymphohistiocytosis , Joanne Choi , Ying Huang , Tina Carter , Janssen Biotech Inc , Exchange Commission On , American Society Of Clinical Oncology , Linkedin , Twitter , European Hematology Association , Drug Administration , Chinese Center , Legend Biotech Corporation , Corporate Communications , European Union , European Medicines Agency , Drug Evaluation Of National Medical Products Administration , Committee For Medicinal Products Human Use , American Cancer Society , Biotech Corporation , Legend Biotech , Clinical Oncology , Annual Meeting , Chief Executive Officer , Hematologic Malignancies Plasma Cell Dyscrasia , Updated Clinical Data , Biological Correlative Analysis , Multiple Myeloma , Early Relapse After Initial Therapy , Refractory Multiple Myeloma , Year Post , Lenalidomide Refractory Patients , Progressive Multiple Myeloma After , Correlative Analyses , Treatment Patterns , Optum Database , Current Standard , Subgroup Analyses , Real Life Current Standard , Refractory Multiple , Patient Reported Outcomes , Triple Class Exposed Multiple Myeloma , Real World Clinical Practice , Triple Class Exposed Patients , Adjusted Comparisons Based , Janssen Biotech , Medicinal Products , Human Use , Therapy Designation , Breakthrough Therapy Designation , Orphan Drug Designation , European Commission , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Nerve Palsies , Recurrent Cytopenias , Igg Hypersensitivity Reactions , Use Machines , Prescribing Information , Boxed Warning , Note Regarding Forward Looking Statements , Private Securities Litigation Reform Act , Drug Evaluation , National Medical Products Administration , Investigational New Drug , Annual Report , Exchange Commission , Accessed May , Statistics About Multiple Myeloma , Accessed February , Senior Manager , Investor Relations , Corporate Communications Lead , Legend , Biotech , Highlight , Ontinued , Progress , Treatment , Multiple , Myeloma , Ith , Pdated , Data , Rom , Cma , Studies , 022 , Disco ,